Ferring Pharmaceuticals Inc. of Parsippany faces a growing number of suits over alleged manufacturing defects that reduced the efficacy of its fertility drug, Bravelle.

The suits stem from  the company’s voluntary recall of Bravelle made between March 2014 and October 2015. The recalls were made after the company’s internal quality monitoring revealed that certain lots of the drug did not meet its potency specifications.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]